Abstract

Novel therapies for the treatment of colitis are required. We therefore examined the potential value of the trefoil factor family 1 (TFF1) peptide and epidermal growth factor (EGF) alone and in combination. Effects of TFF1-Cys⁵⁸±EGF on an in vitro HT29 cell wounding model of restitution showed synergistic activity when used in combination. In addition, animals had colitis induced by adding 4% dextran sulphate sodium (DSS) to the drinking water for 7 days and they also received twice daily subcutaneous injections of test peptides. Treatment with TFF1-Cys⁵⁸ alone (100 μg/kg) reduced histological colitis score by 22%, but the TFF1-Ser⁵⁸ variant was ineffective. In a second study, TFF1-Cys⁵⁸ reduced histological colitis score by 15%, EGF (600 μg/kg) by 26%, and an additive response (42% reduction) was demonstrated when used together (P<0.01 versus either peptide given alone). Similar results were found using tissue myeloperoxidase (MPO) activity as a marker of inflammation. Where clinical risk/benefit seems justified, these initial studies suggest that combination therapy of systemic EGF and TFF peptides may prove useful for treatment of colitis in patients with disease extending beyond the reach of topical (enema) therapy.

Author Keywords: Inflammation; Gut repair; Recombinant peptides; Inflammatory bowel disease

Corresponding author. Tel.: +44-208-383-3266; fax: +44-208-749-3436.